Cargando…
Clopidogrel in Orthopaedic patients: a review of current practice in Scotland
BACKGROUND: Clopidogrel bisulfate is an antiplatelet agent used to prevent ischaemic events in patients with vascular disease. Current guidelines recommend withholding clopidogrel for 7 days pre-operatively. However these are not based on orthopaedic patients. We therefore decided to survey current...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1894781/ https://www.ncbi.nlm.nih.gov/pubmed/17531090 http://dx.doi.org/10.1186/1477-9560-5-6 |
_version_ | 1782133877089763328 |
---|---|
author | Joseph, Jibu J Pillai, Anand Bramley, Diane |
author_facet | Joseph, Jibu J Pillai, Anand Bramley, Diane |
author_sort | Joseph, Jibu J |
collection | PubMed |
description | BACKGROUND: Clopidogrel bisulfate is an antiplatelet agent used to prevent ischaemic events in patients with vascular disease. Current guidelines recommend withholding clopidogrel for 7 days pre-operatively. However these are not based on orthopaedic patients. We therefore decided to survey current orthopaedic practice to see whether this complied with available clinical data. METHOD: A questionnaire was sent to all orthopaedic consultants in Scotland. Four haematology departments, and the manufacturers, were contacted to ask for their recommendations, and a database search was performed. RESULTS: 140 questionnaires were sent with a 60.7% response. 84.7% of respondents have encountered patients on clopidogrel. Of those, 13.9% did not routinely stop it, and 86.1% stopped it 5–21 days pre-operatively (47.2% at 7 days). 45.9% had a unit policy on stopping clopidogrel, and the majority (69.4%) did not consult their haematology department prior to instituting their policy. Increased peri-operative bleeding was the most reported complication (22.6%). However this was only noted in those who stopped clopidogrel greater-than 7 days pre-operatively. Haematology advice ranged from continuing clopidogrel peri-operatively to stopping it 7 days pre-operatively and starting low-molecular-weight-heparin for thrombo-prophylaxis. The manufacturers suggested stopping clopidogrel 7 days pre-operatively. An internet search did not reveal any data on the effect of clopidogrel peri-operatively in orthopaedic patients. DISCUSSION: Recommendations on stopping clopidogrel have evolved from studies conducted on patients undergoing cardio-thoracic surgery. There is no data available on the effect of clopidogrel in orthopaedic practice. Our survey indicates that increased bleeding has not been found in patients who continue clopidogrel peri-operatively. Almost half of respondents complied with current recommendations, stopping clopidogrel 7 days pre-operatively. However there remains a lack of consensus amongst orthopaedic surgeons. Currently elective patients should stop clopidogrel 7 days pre-operatively, and emergency patients should stop clopidogrel on admission, however their operation should not be delayed due to clopidogrel usage. |
format | Text |
id | pubmed-1894781 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-18947812007-06-20 Clopidogrel in Orthopaedic patients: a review of current practice in Scotland Joseph, Jibu J Pillai, Anand Bramley, Diane Thromb J Review BACKGROUND: Clopidogrel bisulfate is an antiplatelet agent used to prevent ischaemic events in patients with vascular disease. Current guidelines recommend withholding clopidogrel for 7 days pre-operatively. However these are not based on orthopaedic patients. We therefore decided to survey current orthopaedic practice to see whether this complied with available clinical data. METHOD: A questionnaire was sent to all orthopaedic consultants in Scotland. Four haematology departments, and the manufacturers, were contacted to ask for their recommendations, and a database search was performed. RESULTS: 140 questionnaires were sent with a 60.7% response. 84.7% of respondents have encountered patients on clopidogrel. Of those, 13.9% did not routinely stop it, and 86.1% stopped it 5–21 days pre-operatively (47.2% at 7 days). 45.9% had a unit policy on stopping clopidogrel, and the majority (69.4%) did not consult their haematology department prior to instituting their policy. Increased peri-operative bleeding was the most reported complication (22.6%). However this was only noted in those who stopped clopidogrel greater-than 7 days pre-operatively. Haematology advice ranged from continuing clopidogrel peri-operatively to stopping it 7 days pre-operatively and starting low-molecular-weight-heparin for thrombo-prophylaxis. The manufacturers suggested stopping clopidogrel 7 days pre-operatively. An internet search did not reveal any data on the effect of clopidogrel peri-operatively in orthopaedic patients. DISCUSSION: Recommendations on stopping clopidogrel have evolved from studies conducted on patients undergoing cardio-thoracic surgery. There is no data available on the effect of clopidogrel in orthopaedic practice. Our survey indicates that increased bleeding has not been found in patients who continue clopidogrel peri-operatively. Almost half of respondents complied with current recommendations, stopping clopidogrel 7 days pre-operatively. However there remains a lack of consensus amongst orthopaedic surgeons. Currently elective patients should stop clopidogrel 7 days pre-operatively, and emergency patients should stop clopidogrel on admission, however their operation should not be delayed due to clopidogrel usage. BioMed Central 2007-05-25 /pmc/articles/PMC1894781/ /pubmed/17531090 http://dx.doi.org/10.1186/1477-9560-5-6 Text en Copyright © 2007 Joseph et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Joseph, Jibu J Pillai, Anand Bramley, Diane Clopidogrel in Orthopaedic patients: a review of current practice in Scotland |
title | Clopidogrel in Orthopaedic patients: a review of current practice in Scotland |
title_full | Clopidogrel in Orthopaedic patients: a review of current practice in Scotland |
title_fullStr | Clopidogrel in Orthopaedic patients: a review of current practice in Scotland |
title_full_unstemmed | Clopidogrel in Orthopaedic patients: a review of current practice in Scotland |
title_short | Clopidogrel in Orthopaedic patients: a review of current practice in Scotland |
title_sort | clopidogrel in orthopaedic patients: a review of current practice in scotland |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1894781/ https://www.ncbi.nlm.nih.gov/pubmed/17531090 http://dx.doi.org/10.1186/1477-9560-5-6 |
work_keys_str_mv | AT josephjibuj clopidogrelinorthopaedicpatientsareviewofcurrentpracticeinscotland AT pillaianand clopidogrelinorthopaedicpatientsareviewofcurrentpracticeinscotland AT bramleydiane clopidogrelinorthopaedicpatientsareviewofcurrentpracticeinscotland |